Interleukin-31 monoclonal antibody
US-10421807-B2 · Sep 24, 2019 · US
Highly specific zika neutralizing human antibodies
US12534517B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12534517-B2 |
| Application number | US-201816765509-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2018 |
| Priority date | Nov 21, 2017 |
| Publication date | Jan 27, 2026 |
| Grant date | Jan 27, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using the antibodies and antigen-binding fragments.
First claim
Opening claim text (preview).
We claim: 1 . A method of treating a subject with Zika virus, comprising administering an effective amount of a composition to the subject, wherein the composition comprises: (a) an antibody or an antigen-binding antibody fragment that binds Domain I of Zika virus (ZIKV) Envelope protein (EDI), binds ZIKV strain MR766, or binds ZIKV Envelope protein III (EDIII), wherein the antibody or antigen-binding antibody fragment comprises a heavy chain variable region and a light chain variable region, and wherein: (i) the heavy chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 1 and the light chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 2; or (ii) the heavy chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 3 and the light chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 4; and (b) a pharmaceutically acceptable carrier. 2 . The method of claim 1 , wherein the antigen-binding antibody fragment is an scFv. 3 . The method of claim 1 , wherein the antibody is a full-length antibody. 4 . The method of claim 3 , wherein the full-length antibody is an IgG molecule. 5 . The method of claim 1 , wherein the antibody or the antigen-binding antibody fragment does not neutralize Dengue viruses 1-4. 6 . The method of claim 1 , wherein the antibody or the antigen-binding antibody fragment is encoded by a nucleic acid. 7 . The method of claim 1 , wherein the antibody is a human antibody. 8 . The method of claim 1 , wherein the composition is administered intramuscularly, subcutaneously, or intravenously. 9 . The method of claim 1 , wherein the subject is a human subject.
Assignees
Inventors
Classifications
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Single chain antibody (scFv) · CPC title
Complementarity determining region [CDR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12534517B2 cover?
- Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using the antibodies and antigen-binding fragments.
- Who is the assignee on this patent?
- The Univ Of Vermont And State Agricultural College, Univ North Carolina Chapel Hill
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).